The Medicines and Healthcare Regulatory Agency (MHRA) has received reports of ‘a very small number of people’ who have been hospitalised after using ‘potentially fake’ weight-loss pens, it has announced.
The regulator has seized 369 potentially fake Ozempic (semaglutide) pens since January, and has also received reports of fake Saxenda (liraglutide) pens that have been obtained by patients in the UK through non-legitimate routes.
And it has urged patients to only access weight-loss medicines via legitimate routes.
Saxenda is authorised in the UK for weight loss, with diet and exercise, while Ozempic has been authorised for the treatment of adults with type 2 diabetes, also with diet and exercise. It is not authorised for weight loss, but it is commonly used off-label for that purpose.
An MHRA spokesperson said: ‘Buying prescription-only medicines online without a prescription poses a direct danger to health.
‘With any medicines bought outside of the legal supply chain, the contents may not match the ingredients on the label.
‘Serious side effects reported of those hospitalised, including hypoglycaemic shock and coma, indicate that the pens may contain insulin rather than semaglutide.
‘If anyone has a concern about their health, they should visit their GP or pharmacist, get a correct diagnosis and if medicines are prescribed, obtain them from a legitimate source.’
MHRA chief safety officer Dr Alison Cave said: ‘Buying products such as Ozempic or Saxenda without a prescription, from illegally trading suppliers, significantly increases the risk of receiving something which is either fake or not licensed for use in the UK.
‘Products purchased in this way do not meet our strict quality and safety standards, and taking such medicines may put your health at significant risk.
‘We are advising all members of the public not to use any pre-filled weight loss pens they may have bought online and instead to report it to us so that we can investigate and take any necessary action.’
Health minister Will Quince said: ‘No one should put profit before the needs of patients, but fraudsters selling black market medicines like this are extremely dangerous and can put people’s health at risk.
‘The medical advice is clear: patients should only use medicines like Ozempic or Saxenda where they’ve been prescribed it by a legitimate source, such as their GP or another legitimate prescriber.
‘The MHRA have our full support in cracking down on these illegal online suppliers to ensure that patients are protected.’
Earlier this month, the MHRA said that pre-filled pens falsely labelled as Ozempic had been identified in the UK supply chain, but that they were identified before reaching UK patients, and that all affected pens were recalled and accounted for.
Shortages of GLP-1 receptor agonists like semaglutide are expected to continue for at least the next year, with pharmacists, GPs, government and patient groups raising concerns that an increase in off-license demand for weight loss was putting supply at risk for patients with diabetes.
A version of this article first appeared on our sister site Pulse.
Keep your clinical knowledge up to date with The Pharmacist
Extend your learning and record your learning outcomes
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.